Xenon Announces Appointment of VP, Discovery Research

    VANCOUVER, Canada, Feb. 6 /CNW/ -- Xenon Pharmaceuticals Inc., a drug
discovery and development company, is pleased to announce today that it has
appointed Charles J. Cohen as Vice President, Discovery Research.
    "We are delighted to welcome Charlie to the Xenon team," commented Simon
Pimstone, Xenon's President and CEO. "Charlie brings a unique combination of
drug discovery experience and leadership including in areas that are highly
relevant to Xenon such as pain.  With a drug candidate for pain currently in
clinical trials, and a backup compound expected to follow, we are certain that
Charlie's background will be of great benefit to Xenon.  In addition to his
experience in the pain area, Charlie brings broad and diverse expertise which
will be applicable to our multiple discovery and pre-clinical programs."
    Dr. Cohen has spent the past approximately 25 years in the
pharmaceutical/biotechnology industry with positions at Bayer Pharmaceuticals,
Merck & Co and Vertex Pharmaceuticals. He held senior scientific positions and
has published widely in the area of pain and more broadly in cellular
neuroscience and neurology. Dr. Cohen received his PhD in Biophysics and
Theoretical Biology from the University of Chicago.
    About Xenon Pharmaceuticals Inc.
    Xenon is a privately owned, clinical genetics-based drug discovery and
development company engaged in developing small molecule therapies focusing in
the areas of Pain, Diabetes/Obesity, Anemia and Iron Overload.  Xenon has
partnerships with Novartis Pharma AG, Roche and Takeda Pharmaceutical Company
Ltd.  For more information, visit the Company's website at
    This release contains forward-looking statements that are not based on
historical fact. These forward-looking statements involve risks, uncertainties
and other factors that may cause the actual results, events or developments to
be materially different from those expressed or implied by such
forward-looking statements. Readers are cautioned not to place undue reliance
on such forward-looking statements.

For further information:

For further information: Dr. Simon Pimstone, President & CEO, 
ddunn@xenon-pharma.com, or Vijay Sondhi, CFO & COO,  vsondhi@xenon-pharma.com,
both of Xenon Pharmaceuticals Inc.,  +1-604-484-3300 Web Site:

Organization Profile

Xenon Pharmaceuticals Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890